Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Xie, Songbo ^a   Chen, Miao ^a   Yan, Bing ^a   He, Xianfei ^a   Chen, Xiwen ^a   Li, Dengwen ^a  

^a NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S6 KINASE; AUTACOID; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MACROPHAGE MIGRATION; MONOCYTE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL ADHESION; CELL LINE; CELL MOTION; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; MACROPHAGE; METABOLISM; PHOSPHORYLATION; SECRETION (PROCESS);

CELL ADHESION; CELL LINE; CELL MOVEMENT; CYTOKINES; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; MACROPHAGES; MONOCYTES; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899546121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094496     Document Type: Article

References (42)

1. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, et al. (2012) Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 24: 331-341.
2. Desmedt M, Rottiers P, Dooms H, Fiers W, Grooten J (1998) Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses. J Immunol 160: 5300-5308. (Pubitemid 28267817)
3. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, et al. (2013) Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 38: 792-804.
4. Curat CA, Miranville A, Sengenes C, Diehl M, Tonus C, et al. (2004) From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 53: 1285-1292. (Pubitemid 38569015)
5. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, et al. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447: 1116-1120. (Pubitemid 47014427)
6. Cerami A (1992) Inflammatory cytokines. Clin Immunol Immunopathol 62: S3-10.
7. Trifilo MJ, Bergmann CC, Kuziel WA, Lane TE (2003) CC chemokine ligand 3 (CCL3) regulates CD8(+) -T-cell effector function and migration following viral infection. J Virol 77: 4004-4014. (Pubitemid 36350941)
8. Wynn TA, Chawla A, Pollard JW (2013) Macrophage biology in development, homeostasis and disease. Nature 496: 445-455.
9. Dituri F, Mazzocca A, Giannelli G, Antonaci S (2011) PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol 2011: 947858.
10. Goldbach-Mansky R (2012) Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 167: 391-404.
11. Ohl K, Tenbrock K (2011) Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011: 432595.
12. O'Shea JJ, Ma A, Lipsky P (2002) Cytokines and autoimmunity. Nat Rev Immunol 2: 37-45. (Pubitemid 37328774)
13. McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, et al. (2011) Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 60: 1688-1698.
14. Boden G (2011) Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 18: 139-143.
15. Kaplan DR, Whitman M, Schaffhausen B, Pallas DC, White M, et al. (1987) Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell 50: 1021-1029.
16. Whitman M, Kaplan DR, Schaffhausen B, Cantley L, Roberts TM (1985) Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315: 239-242. (Pubitemid 15064453)
17. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF (2008) The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187-198. (Pubitemid 351688437)
18. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, et al. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204.
19. Araki N, Hatae T, Furukawa A, Swanson JA (2003) Phosphoinositide-3- kinase-independent contractile activities associated with Fcgamma-receptor- mediated phagocytosis and macropinocytosis in macrophages. J Cell Sci 116: 247-257. (Pubitemid 36163866)
20. Fortin CF, Cloutier A, Ear T, Sylvain-Prevost S, Mayer TZ, et al. (2011) A class IA PI3K controls inflammatory cytokine production in human neutrophils. Eur J Immunol 41: 1709-1719.
21. Soond DR, Bjorgo E, Moltu K, Dale VQ, Patton DT, et al. (2010) PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115: 2203-2213.
22. Shi X, Liu M, Li D, Wang J, Aneja R, et al. (2012) Cep70 contributes to angiogenesis by modulating microtubule rearrangement and stimulating cell polarization and migration. Cell Cycle 11: 1554-1563.
23. Li D, Xie S, Ren Y, Huo L, Gao J, et al. (2011) Microtubule-associated deacetylase HDAC6 promotes angiogenesis by regulating cell migration in an EB1-dependent manner. Protein Cell 2: 150-160.
24. Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18: 77-82. (Pubitemid 43740454)
25. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
26. Utsugi M, Dobashi K, Ono A, Ishizuka T, Matsuzaki S, et al. (2009) PI3K p110beta positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role. J Immunol 182: 5225-5231.
27. Polumuri SK, Toshchakov VY, Vogel SN (2007) Role of phosphatidylinositol- 3 kinase in transcriptional regulation of TLR-induced IL-12 and IL-10 by Fc gamma receptor ligation in murine macrophages. J Immunol 179: 236-246. (Pubitemid 46986539)
28. Hortner M, Nielsch U, Mayr LM, Johnston JA, Heinrich PC, et al. (2002) Suppressor of cytokine signaling-3 is recruited to the activated granulocytecolony stimulating factor receptor and modulates its signal transduction. J Immunol 169: 1219-1227. (Pubitemid 34809162)
29. Jimenez S, Torres M, Vizuete M, Sanchez-Varo R, Sanchez-Mejias E, et al. (2011) Age-dependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J Biol Chem 286: 18414-18425.
30. Ozaita A, Puighermanal E, Maldonado R (2007) Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 102: 1105-1114. (Pubitemid 47174245)
31. Ahmad A, Biersack B, Li Y, Kong D, Bao B, et al. (2013) Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment. Anticancer Agents Med Chem 13: 1014-1024.
32. Xie C, Patel R, Wu T, Zhu J, Henry T, et al. (2007) PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr. Int Immunol 19: 509-522. (Pubitemid 46523398)
33. Thorley AJ, Ford PA, Giembycz MA, Goldstraw P, Young A, et al. (2007) Differential regulation of cytokine release and leukocyte migration by lipopolysaccharide-stimulated primary human lung alveolar type II epithelial cells and macrophages. J Immunol 178: 463-473. (Pubitemid 46033630)
34. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, et al. (2009) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182: 4415-4422.
35. Zajac E, Schweighofer B, Kupriyanova TA, Juncker-Jensen A, Minder P, et al. (2013) Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9. Blood 122: 4054-4067.
36. Chanput W, Mes JJ, Savelkoul HF, Wichers HJ (2013) Characterization of polarized THP-1 macrophages and polarizing ability of LPS and food compounds. Food Funct 4: 266-276.
37. Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, et al. (2011) Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 12: 13.
38. Hammond MD, Ai Y, Sansing LH (2012) Gr1+ Macrophages and Dendritic Cells Dominate the Inflammatory Infiltrate 12 Hours After Experimental Intracerebral Hemorrhage. Transl Stroke Res 3: s125-s131.
39. Stewart CR, Tseng AA, Mok YF, Staples MK, Schiesser CH, et al. (2005) Oxidation of low-density lipoproteins induces amyloid-like structures that are recognized by macrophages. Biochemistry 44: 9108-9116. (Pubitemid 40943225)
40. Chiba T, Umegaki K (2013) Pivotal roles of monocytes/macrophages in stroke. Mediators Inflamm 2013: 759103.
41. Xie S, Dong B, Sun X, Tala, He X, et al. (2014) Identification of a cytoplasmic linker protein as a potential target for neovascularization. Atherosclerosis 233: 403-409.
42. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, et al. (2003) Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 100: 4736-4741. (Pubitemid 36457799)